Our Mission

Welcome to KAIDA BioPharma, a clinical-stage oncology company advancing KAD-101, a first-in-class prolactin receptor antagonist designed to disrupt tumor survival signaling in ovarian cancer. The company is focused on developing targeted therapies for treatment-resistant disease through a biomarker-driven clinical strategy.